Trial roll out for anti-viral treatment of people with a positive COVID test

Posted on December 21st, 2021

Anti-viral treatment for people with a positive COVID test:

Trial participation for the general public 

There are two routes into the trial for potential participants: 

• Self-referral via the trial website: https://www.panoramictrial.org/
• An approach by trial teams in Health Boards to people with a positive COVID test (list provided daily by Test & Protect) to inform them of the study and undertake the eligibility check and to take consent. Not all Boards will support this route (NHS Highland RD&I are currently evaluating how we can best support the study across our Health Board).

Participant inclusion criteria: 

• Symptoms attributable to COVID-19 started within the past 5 days and ongoing
• A positive PCR SARS-CoV-2 test
• Aged ≥50 years
• OR aged 18-49 years with a known underlying chronic health condition considered to make them clinically vulnerable.

High-risk patients 

Additionally, there will be limited deployment of the anti-viral treatments to patients that are in the high-risk group (same patients as the vaccine high-risk group). Patients will be informed via letter or email if they are eligible to receive these treatments directly should they test positive.

The first Investigative Medicinal product to be tested is Molnupiravir (Brand name: Lagevrio)

For the high-risk Group patients should be directed to the Health Board single point of contact telephone number. The single point of contact telephone numbers will be published on NHS Inform once services go-live on 16 December 2021.

Other patients requesting to participate in the trial should be referred to the trial website at  https://www.panoramictrial.org/